Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Has Average Price Target of $103.33

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has earned a consensus recommendation of “Hold” from the twenty-three analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, fifteen have given a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $104.47.

ZBH has been the subject of several research analyst reports. Argus reaffirmed a “buy” rating and set a $125.00 price target on shares of Zimmer Biomet in a research note on Thursday. BMO Capital Markets reaffirmed a “market perform” rating on shares of Zimmer Biomet in a research note on Monday, September 28th. Stifel Nicolaus increased their target price on shares of Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, August 6th. UBS Group reiterated a “buy” rating and issued a $120.00 target price on shares of Zimmer Biomet in a research report on Thursday, August 6th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, August 5th.

Zimmer Biomet Trading Down 0.2%

Shares of Zimmer Biomet stock opened at $98.65 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. Zimmer Biomet has a 1 year low of $79.12 and a 1 year high of $104.15. The firm has a market cap of $18.82 billion, a PE ratio of 24.00, a PEG ratio of 1.86 and a beta of 0.49. The company has a 50 day simple moving average of $95.13 and a two-hundred day simple moving average of $91.52.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. The firm had revenue of $2.18 billion for the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Analysts expect that Zimmer Biomet will post 8.54 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.36%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, insider Kevin R. Thornal sold 5,691 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Chad Phipps sold 3,000 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the transaction, the insider owned 65,231 shares in the company, valued at $6,415,468.85. This represents a 4.40% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 1.28% of the company’s stock.

Hedge Funds Weigh In On Zimmer Biomet

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in Zimmer Biomet during the second quarter valued at approximately $1,344,282,000. Primecap Management Co. CA purchased a new stake in Zimmer Biomet in the second quarter worth approximately $328,578,000. Bank of America Corp DE bought a new stake in Zimmer Biomet in the 2nd quarter worth approximately $187,480,000. Auto Owners Insurance Co grew its position in Zimmer Biomet by 8,892.0% in the 4th quarter. Auto Owners Insurance Co now owns 2,009,712 shares of the medical equipment provider’s stock worth $180,713,000 after purchasing an additional 1,987,362 shares during the period. Finally, Equity Investment Corp bought a new stake in Zimmer Biomet in the 2nd quarter worth approximately $144,748,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.